Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13618809 | 0.85 | MAPT (0.44) | ALDH1A1POLBSMN1; SMN2NPC1GAA | |
| SCHEMBL922696 | 0.85 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2NPC1GAA | |
| SCHEMBL19171550 | 0.84 | SMN1; SMN2 (0.50) | ALDH1A1POLBSMN1; SMN2NPC1GAA | |
| SCHEMBL5505398 | 0.83 | ALDH1A1 (0.50) | ALDH1A1POLBSMN1; SMN2NPC1GAA | |
| SCHEMBL12747921 | 0.83 | ALDH1A1 (0.41) | ALDH1A1POLBSMN1; SMN2NPC1GAA | |
| SCHEMBL14094895 | 0.83 | ALDH1A1 (0.42) | ALDH1A1POLBSMN1; SMN2NPC1GAA | |
| SCHEMBL1121578 | 0.81 | — | — | |
| SCHEMBL155565 | 0.81 | — | — | |
| SCHEMBL6356662 | 0.81 | — | — | |
| SCHEMBL1121579 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873310-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11780873-B2 | Highly potent multimeric e-selectin antagonists | GLYCOMIMETICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11712446-B2 | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof | GLYCOMIMETICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | GLYCOMIMETICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230165882-A1 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | GLYCOMIMETICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230127765-A1 | COMBINATION OF T-CELL CHECKPOINT INHIBITORS WITH INHIBITORS OF E-SELECTIN OR CXCR4, OR WITH HETEROBIFUNCTIONAL INHIBITORS OF BOTH E-SELECTIN AND CXCR4 | GLYCOMIMETICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20180155332-A1 | SMALL MOLECULE BASED ANTIBODY-RECRUITING COMPOUNDS FOR CANCER TREATMENT | YALE UNIVERSITY | 2018-06-07 | — | — | US | disclosed |
| US-20170305951-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170296566-A9 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS | GLYCOMIMETICS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20160333043-A1 | E-Selectin Antagonists Modified By Macrocycle Formation to the Galactose | GLYCOMIMETICS, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160243145-A1 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS | GLYCOMIMETICS, INC. (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155332-A1 | SMALL MOLECULE BASED ANTIBODY-RECRUITING COMPOUNDS FOR CANCER TREATMENT | PLAUR, C5AR1, C3AR1 | ALDH1A1 3982/4885POLB 3750/4885SMN1; SMN2 2701/4885 |
| US-11873310-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | ALDH1A1 424/4885POLB 273/4885SMN1; SMN2 2746/4885 |
| US-20160333043-A1 | E-Selectin Antagonists Modified By Macrocycle Formation to the Galactose | SELE, SELPLG, SELL | ALDH1A1 655/4885POLB 4707/4885SMN1; SMN2 3759/4885 |
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | SELE, SELPLG, MCL1 | ALDH1A1 1037/4885POLB 2970/4885SMN1; SMN2 3305/4885 |
| US-20170296566-A9 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS | SELE, SELP, SELPLG | ALDH1A1 636/4885POLB 2286/4885SMN1; SMN2 3010/4885 |
| US-11712446-B2 | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof | SELE, SELL, SELP | ALDH1A1 750/4885POLB 769/4885SMN1; SMN2 1733/4885 |
| US-20230165882-A1 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | FLT3, SELE, SELL | ALDH1A1 1066/4885POLB 2661/4885SMN1; SMN2 3878/4885 |
| US-20230127765-A1 | COMBINATION OF T-CELL CHECKPOINT INHIBITORS WITH INHIBITORS OF E-SELECTIN OR CXCR4, OR WITH HETEROBIFUNCTIONAL INHIBITORS OF BOTH E-SELECTIN AND CXCR4 | SELE, CD274, CXCR3 | ALDH1A1 2125/4885POLB 3467/4885SMN1; SMN2 2989/4885 |
| US-11780873-B2 | Highly potent multimeric e-selectin antagonists | SELE, SELP, SELPLG | ALDH1A1 773/4885POLB 4162/4885SMN1; SMN2 2259/4885 |
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | SELP, SELE, SELPLG | ALDH1A1 1201/4885POLB 3151/4885SMN1; SMN2 2397/4885 |
| US-20160243145-A1 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS | SELE, SELP, SELPLG | ALDH1A1 636/4885POLB 2286/4885SMN1; SMN2 3010/4885 |
| US-20170305951-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | CXCL12, CXCR4, SELE | ALDH1A1 502/4885POLB 3432/4885SMN1; SMN2 3650/4885 |
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | ALDH1A1 759/4885POLB 3988/4885SMN1; SMN2 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.